Inspection Record

QuVa Pharma, Inc. — FDA 483 Findings

US FDAInspected 2025-03-04Published 2025-05-07 5 findingsTraining and personnelLaboratory and QC controlsDeviation, CAPA, and investigationOther quality system

Inspectors Logan T WilliamsThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Employees engaged in the manufacture, processing and packing of a drug product lack the training required to perform their assigned functions.

2Laboratory and QC controls

The accuracy specificity and reproducibility of test methods have not been established.

3Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been akeady distributed.

4Laboratory and QC controls

The statistical quality control criteria fail to include appropriate rejection levels.

5Other quality system

Written procedures for sanitation are not followed.

About this record

Extracted automatically from the document US FDA published on 2025-05-07. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

QuVa Pharma, Inc. findings history — including this company's other documents US FDA documents, 2025 Go to Findings search